Transplantation, Renal Completed Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Renal Transplantation

IndicationStatusPhase
DBCOND0032528 (Transplantation, Renal)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00214266A Pilot Study of Campath-1H Induction Therapy Combined With CellCeptĀ® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal TransplantationTreatment